Schlusskurs
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
16.26 CNY | +0.43% | +10.01% | +29.98% |
Kurzporträt
Mitarbeiterzahl: 476
Umsatz nach Geschäftsbereich
CNY in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Crude Urokinase
43,0
%
| 103 | 42,3 % | 177 | 43,0 % | +71.46% |
Ulinastatin Crude
19,3
%
| 40 | 16,4 % | 80 | 19,3 % | +98.15% |
Senna Granules
15,6
%
| 50 | 20,3 % | 64 | 15,6 % | +29.63% |
New HIV Drug (Enomitide Tablets)
11,9
%
| - | - | 49 | 11,9 % | - |
New HIV Drug (EnovirineTablets)
6,0
%
| 33 | 13,7 % | 25 | 6,0 % | -26.15% |
HIV Diagnostic Reagents
1,8
%
| 12 | 5,0 % | 7 | 1,8 % | -40.95% |
Bacillus Cereus Tablets
1,0
%
| 3 | 1,4 % | 4 | 1,0 % | +19.19% |
Other Crude Human Protein
0,8
%
| 0 | 0,0 % | 3 | 0,8 % | +6’509.67% |
Other Business
0,6
%
| 1 | 0,6 % | 2 | 0,6 % | +69.38% |
Other Generic Drugs
0,0
%
| 0 | 0,0 % | 0 | 0,0 % | -997.00% |
Umsatz je Region
CNY in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
China
100,0
%
| 244 | 100,0 % | 411 | 100,0 % | +68.44% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Jie Zhang
CEO | Chief Executive Officer | 54 | - |
Chuanhong Zhu
DFI | Director of Finance/CFO | 53 | 16.09.23 |
He Liang Fu
CHM | Chairman | 63 | 01.01.14 |
Qi Hong
CTO | Chief Tech/Sci/R&D Officer | 61 | 19.01.21 |
Jun Wang
COO | Chief Operating Officer | 50 | 01.01.14 |
Guang Rong Wang
BRD | Director/Board Member | 48 | 01.01.15 |
Wei Xuan Zhou
IRC | Investor Relations Contact | 34 | 01.08.20 |
Yan Liu
SEC | Corporate Secretary | 42 | 14.03.23 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
He Liang Fu
CHM | Chairman | 63 | 01.01.14 |
Guang Ji Wang
BRD | Director/Board Member | 71 | 09.05.19 |
Xiao Yan Qi
BRD | Director/Board Member | 61 | 10.03.22 |
Guang Rong Wang
BRD | Director/Board Member | 48 | 01.01.15 |
Jun Wang
COO | Chief Operating Officer | 50 | 01.01.14 |
Heng Yu
CHM | Chairman | 44 | 01.12.09 |
Feng Ying He
BRD | Director/Board Member | 41 | 01.12.14 |
Zijian Guo
BRD | Director/Board Member | 63 | 15.09.23 |
Jie Zhang
CEO | Chief Executive Officer | 54 | - |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 420 782 808 | 185 754 481 ( 44,14 %) | 0 | 44,14 % |
Unternehmenskontakt
Jiangsu Aidea Pharmaceutical Co., Ltd.
No.69 New Ganquan West Road Hanjiang District
225008, Yangzhou
+
http://www.aidea.com.cnSektor
Umsatz nach Geschäftsbereich
% 1. Jan. | Kap. | |
---|---|---|
+29.98% | 943 Mio. | |
-3.35% | 88.91 Mrd. | |
+2.76% | 41.25 Mrd. | |
-14.60% | 31.99 Mrd. | |
+50.51% | 24.73 Mrd. | |
-14.91% | 15.54 Mrd. | |
-39.93% | 12.07 Mrd. | |
-9.08% | 12.05 Mrd. | |
-15.16% | 12.02 Mrd. | |
+6.22% | 8.84 Mrd. |
- Börse
- Aktien
- 688488 Aktie
- Unternehmen Jiangsu Aidea Pharmaceutical Co., Ltd.